ScholarLens Back to search
2010•Medical RecapitulateRequires access

The Application of Rituximab in Idiopathic Thrombocytopenic Purpura

Xiaomin Wang

Open publisher page 0 citations

Abstract

It has been confirmed that idiopathic thrombocytopenic purpura(ITP)was a clinical syndrome because platets were much destroied by immunologic mechanism,it is also called immune thrombocytopenic purpura.The anti-CD20 monoclonal antibody rituximab is one of neotype biological response modifiers,it has been used more and more for the treatment of multipal immune disease incluinding idiopathic thrombocytopenic purpura at present.This review article is about rituximab therapy in patients with IPT.

About this research paper

What this paper is about

It has been confirmed that idiopathic thrombocytopenic purpura(ITP)was a clinical syndrome because platets were much destroied by immunologic mechanism,it is also called immune thrombocytopenic purpura.The anti-CD20 monoclonal antibody rituximab is one of neotype biological response modifiers,it has been used more and more for the treatment of multipal immune disease incluinding idiopathic thrombocytopenic purpura at present.This review article is about rituximab therapy in patients with IPT.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

It has been confirmed that idiopathic thrombocytopenic purpura(ITP)was a clinical syndrome because platets were much destroied by immunologic mechanism,it is also called immune thrombocytopenic purpura.The anti-CD20 monoclonal antibody rituximab is one of neotype biological response modifiers,it has been used more and more for the treatment of multipal immune disease incluinding idiopathic thrombocytopenic purpura at present.This review article is about rituximab therapy in patients with IPT.

Key concepts: Thrombocytopenic purpura, Rituximab, Medicine, CD20, Immunology, Immune system, Monoclonal antibody, Antibody

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The Application of Rituximab in Idiopathic Thrombocytopenic Purpura — Research Paper | ScholarLens